Survivin as a novel target protein for reducing the proliferation of cancer cells (Review)
- Authors:
- Dongyu Li
- Chenghao Hu
- Huibin Li
-
Affiliations: Department of Genetics, College of Agricultural and Life Science, University of Wisconsin‑Madison, Madison, WI 53706, USA, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, P.R. China, Department of Burns and Plastic Surgery, People's Hospital of Linyi, Linyi, Shandong 276000, P.R. China - Published online on: March 13, 2018 https://doi.org/10.3892/br.2018.1077
- Pages: 399-406
This article is mentioned in:
Abstract
 |
|
Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
al-Kattan K, Sepsas E, Fountain SW and Townsend ER: Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 12:380–384. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K and Nakagawa K: Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res. 14:6496–6504. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li WL, Lee MR and Cho MY: The small molecule survivin inhibitor YM155 may be an effective treatment modality for colon cancer through increasing apoptosis. Biochem Biophys Res Commun. 471:309–314. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hunter AM, LaCasse EC and Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis. 12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Schimmer AD: Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res. 64:7183–7190. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Li F and Altieri DC: The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 59:3143–3151. 1999.PubMed/NCBI | |
|
Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O and Margolis RL: Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell. 6:183–189. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner S, et al: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 4:21392013. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY: Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tazo Y, Hara A, Onda T and Saegusa M: Bifunctional roles of survivin-Delta Ex3 and survivin-2B for susceptibility to apoptosis in endometrial carcinomas. J Cancer Res Clin. 140:2027–2037. 2014. View Article : Google Scholar | |
|
Liu YB, Gao X, Deeb D, Brigolin C, Zhang Y, Shaw J, Pindolia K and Gautam SC: Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin. Int J Oncol. 45:1735–1741. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 114:1117–1127. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Survivin and IAP proteins in cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tsuneki M and Madri JA: CD44 regulation of endothelial cell proliferation and apoptosis via modulation of CD31 and VE-cadherin expression. J Biol Chem. 289:5357–5370. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeguchi M, Liu J and Kaibara N: Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis. 7:23–29. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng WE, Chen H, Yuan SF, Wu LL, Zhang W, Sun HY and Chen WJ: Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. J BUON. 17:284–290. 2012.PubMed/NCBI | |
|
Shen X, Zheng JY, Shi H, Zhang Z and Wang WZ: Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice. Am J Med Sci. 344:52–58. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Guvenc H, Pavlyukov MS, Joshi K, Kurt H, Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Bhasin D, et al: Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res. 19:631–642. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Garg H, Suri P, Gupta JC, Talwar GP and Dubey S: Survivin: A unique target for tumor therapy. Cancer Cell Int. 16:492016. View Article : Google Scholar : PubMed/NCBI | |
|
Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G and Medema RH: Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J. 22:2934–2947. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Tenev T, Martins LM, Downward J and Lemoine NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 113:4363–4371. 2000.PubMed/NCBI | |
|
Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M and Altieri DC: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 62:2462–2467. 2002.PubMed/NCBI | |
|
Fangusaro JR, Caldas H, Jiang Y and Altura RA: Survivin: An inhibitor of apoptosis in pediatric cancer. Pediatr Blood Cancer. 47:4–13. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res. 5:447–452. 2003.PubMed/NCBI | |
|
Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Véquaud E, Desplanques G, Jézéquel P, Juin P and Barillé-Nion S: Survivin contributes to DNA repair by homologous recombination in breast cancer cells. Breast Cancer Res Treat. 155:53–63. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Yang M, Li B, Liu J and Sun H: Protection effect of survivin protein overexpression on acute myocardial infarction in rats. Int J Clin Exp Med. 8:12995–13000. 2015.PubMed/NCBI | |
|
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.PubMed/NCBI | |
|
Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1:461–466. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wheatley SP: The functional repertoire of survivin's tails. Cell Cycle. 14:261–268. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Dohi T, Xia F and Altieri DC: Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell. 27:17–28. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hagenbuchner J, Kuznetsov AV, Obexer P and Ausserlechner MJ: BIRC5/survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene. 32:4748–4757. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Song Z, Yao X and Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC and Valent P: Cancer stem cells in basic science and in translational oncology: Can we translate into clinical application? J Hematol Oncol. 8:162015. View Article : Google Scholar : PubMed/NCBI | |
|
Stoica G, Lungu G, Martini-Stoica H, Waghela S, Levine J and Smith R III: Identification of cancer stem cells in dog glioblastoma. Vet Pathol. 46:391–406. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, et al: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 17:3333–3355. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 49:333–343. 1978. View Article : Google Scholar : PubMed/NCBI | |
|
Dick JE: Looking ahead in cancer stem cell research. Nat Biotechnol. 27:44–46. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T and Lin J: STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells. Biochem Biophys Res Commun. 416:246–251. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vermeulen L, De Sousa E, Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, et al: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 12:468–476. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mao J, Fan S, Ma W, Fan P, Wang B, Zhang J, Wang H, Tang B, Zhang Q, Yu X, et al: Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis. 5:e10392014. View Article : Google Scholar : PubMed/NCBI | |
|
Cai C and Zhu X: The Wnt/β-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer. Mol Med Rep. 5:1191–1196. 2012.PubMed/NCBI | |
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Blagosklonny MV: Cancer stem cell and cancer stemloids: From biology to therapy. Cancer Biol Ther. 6:1684–1690. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M and Sasamata M: Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, et al: YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. J Hematol Oncol. 8:392015. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng XJ, Lin JC, Ding YF, Zhu L, Ye J and Tu SP: Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues. Oncotarget. 7:7096–7109. 2016.PubMed/NCBI | |
|
Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG and Li F: Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol. 3:179–197. 2012.PubMed/NCBI | |
|
Clemens MR, Gladkov OA, Gartner E, Vladimirov V, Crown J, Steinberg J, Jie F and Keating A: Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 149:171–179. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kudchadkar R, Ernst S, Chmielowski B, Redman BG, Steinberg J, Keating A, Jie F, Chen C, Gonzalez R and Weber J: A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma. Cancer Med. 4:643–650. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et al: A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 24:2601–2606. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, et al: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Koike H, Nitta T, Sekine Y, Arai S, Furuya Y, Nomura M, Matsui H, Shibata Y, Ito K, Oyama T and Suzuki K: YM155 reverses rapamycin resistance in renal cancer by decreasing survivin. J Cancer Res Clin Oncol. 140:1705–1713. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Feng W, Yoshida A and Ueda T: YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun. 435:52–57. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rivadeneira DB, Caino MC, Seo JH, Angelin A, Wallace DC, Languino LR and Altieri DC: Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Sci Signal. 8:ra802015. View Article : Google Scholar : PubMed/NCBI | |
|
Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL and Newton DL: The ‘survivin suppressants’ NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol. 70:207–212. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tang H, Shao H, Yu C and Hou J: Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol. 82:1066–1072. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng SM, Chang YC, Liu CY, Lee JY, Chan HH, Kuo CW, Lin KY, Tsai SL, Chen SH, Li CF, et al: YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Br J Pharmacol. 172:214–234. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng L, Cao L, Xiao PF, Pang L, Wu D, et al: Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer. 12:6192012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Liu Y, Li YF, Yue Y, Yang X and Peng L: Targeting of survivin pathways by YM155 inhibits cell death and invasion in oral squamous cell carcinoma cells. Cell Physiol Biochem. 38:2426–2437. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, et al: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 26:5198–5203. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E and Gonzalez R: A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 29:161–166. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Alexandrescu DT, Gonzales R, Lewis K, Samlowski W, Cranmer L, Catlett J, Kirkwood J, Whitman E, Lawson D, Bartels P, et al: A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma. Mol Cancer Ther. 6:3385S. 2007. | |
|
Rauch A, Hennig D, Schäfer C, Wirth M, Marx C, Heinzel T, Schneider G and Krämer OH: Survivin and YM155: How faithful is the liaison? Biochim Biophys Acta. 1845:202–220. 2014.PubMed/NCBI | |
|
Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF and Fielding A: Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia. 18:616–623. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P and Patel BK: Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther. 10:221–232. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Henry SP, Geary RS, Yu R and Levin AA: Drug properties of second-generation antisense oligonucleotides: How do they measure up to their predecessors? Curr Opin Investig Drugs. 2:1444–1449. 2001.PubMed/NCBI | |
|
Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André V, Kadam S, Burgess M, Slapak C, Olsen AL, et al: Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: A proof-of-concept, first-in-human dose study. Clin Cancer Res. 16:6150–6158. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tanioka M1, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S and Tamura T: Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 68:505–511. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Talbot DC, Davies J, Olsen A, Andre V, Lahn M, Powell E, Kadam S, de Bono J, McHugh P and Ranson M: Pharmacodynamic (PD) evaluation of LYPharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies. J Clin Oncol. 27:35072009. | |
|
Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, et al: Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 7:457–468. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Young JC, Moarefi I and Hartl FU: Hsp90: A specialized but essential protein-folding tool. J Cell Biol. 154:267–273. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hendruschk S, Wiedemuth R, Aigner A, Töpfer K, Cartellieri M, Martin D, Kirsch M, Ikonomidou C, Schackert G and Temme A: RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro-Oncol. 13:1074–1089. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z, Yu B, Zhu J, Huang X, Xie J, Xu S, Yang X, Wang X, Yung BC, Lee LJ, et al: A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia. Nanoscale. 6:9742–9751. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Boukany PE, Morss A, Liao WC, Henslee B, Jung H, Zhang X, Yu B, Wang X, Wu Y, Li L, et al: Nanochannel electroporation delivers precise amounts of biomolecules into living cells. Nat Nanotechnol. 6:747–754. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wen Y and Meng WS: Recent in vivo evidences of particle-based delivery of small-interfering RNA (siRNA) into solid tumors. J Pharm Innov. 9:158–173. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kim VN, Han J and Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Devi GR: siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13:819–829. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Seth S, Matsui Y, Fosnaugh K, Liu Y, Vaish N, Adami R, Harvie P, Johns R, Severson G, Brown T, et al: RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther. 19:928–935. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SJ, Son S, Yhee JY, Choi K, Kwon IC, Kim SH and Kim K: Structural modification of siRNA for efficient gene silencing. Biotechnol Adv. 31:491–503. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng J, Zhang L, Zhang J, Wang X, Ye K, Xi Z, Du Q and Liang Z: Single modification at position 14 of siRNA strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation. FASEB J. 27:4017–4026. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dykxhoorn DM and Lieberman J: Knocking down disease with siRNAs. Cell. 126:231–235. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, Karagiannis E, Love K, Chen D, Zoncu R, et al: Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 31:653–658. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Perez AP, Cosaka ML, Romero EL and Morilla MJ: Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. Int J Nanomedicine. 6:2715–2728. 2011.PubMed/NCBI | |
|
Mamori S, Matsushima M, Matsuura T and Tajiri H: Survivin is expressed in early hepatocellular carcinoma and surrounding hepatitis tissue. Mol Med Rep. 2:911–915. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM and Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 100:751–757. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L, Gessi M, Gallotta V and Scambia G: Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer. 92:271–277. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, et al: Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer. 103:1685–1692. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nasu S, Yagihashi A, Izawa A, Saito K, Asanuma K, Nakamura M, Kobayashi D, Okazaki M and Watanabe N: Survivin mRNA expression in patients with breast cancer. Anticancer Res. 22:1839–1843. 2002.PubMed/NCBI | |
|
Yu J, Leung WK, Ebert MP, Ng EK, Go MY, Wang HB, Chung SC, Malfertheiner P and Sung JJ: Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer. 87:91–97. 2002. View Article : Google Scholar : PubMed/NCBI |
